동물 모델 시장 보고서 : 동물 유형, 기술, 용도, 최종사용자, 지역별(2025-2033년)

The global animal model market size reached USD 1,916 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,151 Million by 2033, exhibiting a growth rate (CAGR) of 5.7% during 2025-2033.

Animal models are living, non-human species used in medical research and investigations. They are frequently selected due to their vast similarities with the genetics, anatomy, and physiology of humans. They assist in obtaining information about the prevention, diagnosis, and treatment of diseases without causing harm to a human. Some of the commonly utilized animal models include rodents, rats, mice, gerbils, guinea pigs, and hamsters. At present, they are widely preferred on account of their availability, ease of handling, and relatively low cost of use.

Animal Model Market Trends:

Presently, there is a continuous increase in the need for personalized medicines across the globe. This, in confluence with a rising prevalence of genetic disorders, such as down syndrome, Crohn's disease, breast cancer, and hemophilia, represents one of the key factors positively influencing the utilization of animal models in the pre-clinical development of drugs by researchers. Apart from this, they are also being utilized in biomedical research, toxicology, physiology, cancer research, neurological research, genetic research, and xenotransplantation around the world. Furthermore, the market is propelled by numerous technological advancements, such as the introduction of CRISPR-Cas9, a genome editing technology, which aids in reducing the time and cost required for enabling the production of animal models with extensive genetic modifications. This technology finds wide applicability in a variety of animals, ranging from early-branching metazoans to primates. Besides this, the sudden outbreak of the contagious coronavirus disease (COVID-19) pandemic is creating a favorable outlook for the market. This can be accredited to the increasing investments by international organizations like World Health Organization (WHO) and government authorities in research and development (R&D) activities to introduce vaccines and antiviral drugs.

Key Market Segmentation:

Breakup by Animal Type:

• Rat
• Mice
• Guinea Pigs
• Rabbits
• Others

Breakup by Technology:

• CRISPR
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Others

Breakup by Application:

• Drug Discovery and Development
• Basic Research
• Others

Breakup by End User:

• Pharma and Biotech Companies
• Academic Research Institutes
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocytogen, Charles River Laboratories International Inc, Envigo, Eurofins Scientific SE, GenOway S.A., Hera BioLabs, JSR Corporation, Ozgene Pty Ltd., PerkinElmer Inc., Taconic Biosciences Inc., The Jackson Laboratory and Trans Genic Inc.

Key Questions Answered in This Report:

• How has the global animal model market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global animal model market?
• What are the key regional markets?
• What is the breakup of the market based on the animal type?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global animal model market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Animal Model Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Animal Type

• 6.1 Rat
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Mice
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Guinea Pigs
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Rabbits
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Technology

• 7.1 CRISPR
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Embryonic Stem Cell Injection
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Nuclear Transfer
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Drug Discovery and Development
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Basic Research
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharma and Biotech Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academic Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Biocytogen
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Charles River Laboratories International Inc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Envigo
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Eurofins Scientific SE
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 GenOway S.A.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
  • 15.3.6 Hera BioLabs
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 JSR Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Ozgene Pty Ltd.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 PerkinElmer Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Taconic Biosciences Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 The Jackson Laboratory
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 Trans Genic Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis